Nebenwirkungen · Zebinix
Zebinix 600 mg tablets · Abschnitt 4.8 · PDF-Seite 49
HOS-120944 · Präparat HOS-095225
Long-term safety data in the paediatric population obtained from open label extensions of the phase III study was consistent with the known safety profile of the product with no new findings of concern. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage bf3d9cffeb0b3be6fe337131d23bbb17abf3198e845ad935db71bf19ce50f4c1 · Zeichen 13993–14551 im Abschnitt